Last edition
News about "9MW2821 ADC"
Mabwell Launches Phase 3 Trial of Nectin-4 ADC 9MW2821 for Triple-Negative Breast Cancer
Mabwell launches Phase 3 study of 9MW2821, the world’s first Nectin-4 ADC for TNBC, marking its fourth pivotal clinical trial.
9MW2821 ADC | 23/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members